The usual key to the quarterly earnings is the amount of cash and cash equivalents available to sustain the organization through the new few Q’s or “runway”.
What matters beyond the spending … are the significant milestones and catalysts in furthering clinical development and trials… and if they have the cash to advance their vision and focus. I still believe companies … strive to fulfill the “sows ear to a silk purse” promise to … unlock … any future value to shareholders.
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at email@example.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors